InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program ...
CLN-049 achieved promising anti-leukemic activity in this heavily pretreated AML population: Anti-leukemic activity was observed at target doses =6 µg/kg (n=23, all AML), with a CRc rate of 30%, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback